Authors

Latest:

Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Panelists discuss how recent research presentations and data updates at the latest scientific meeting have advanced the understanding and treatment landscape of biliary tract cancer (BTC).

Sagar Patel, MD

Latest:

Dr Patel on the Utility of Orca-T in Hematologic Malignancies

Sagar Patel, MD, discusses the utility of the Orca-T platform in patients with hematologic malignancies, highlighting the platform's safety.

John Moroney, MD

Latest:

Dr. Moroney on the Evaluation of COM701 Plus BMS-986207 and Nivolumab in Ovarian Cancer

John Moroney, MD, discusses the evaluation of COM701 plus BMS-986207 and nivolumab in platinum-resistant ovarian cancer.

David L. Saltman, MD, PhD

Latest:

Dr. Saltman on the Use of the DetermaIO Assay to Inform Immunotherapy Use in Advanced-Stage NSCLC

David L. Saltman, MD, PhD, discusses the use of the 27-gene Determa immuno-oncology assay to inform use of single-agent immunotherapy in patients with advanced-stage non–small cell lung cancer.

Jacob G. Scott, MD, DPhil

Latest:

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Catherine Lai, MD, MPH,

Latest:

Dr Lai on NCCN Guideline Updates in AML Maintenance Therapy

Catherine E. Lai, MD, MPH, discusses NCCN guideline updates regarding AML maintenance therapy, sharing how these updates influence treatment decisions.

Andrea Sitlinger, MD, Duke University Cancer Institute

Latest:

Updates in the Management of Hairy Cell Leukemia

Spyridoula Vasileiou, PhD

Latest:

Dr. Vasileiou on the Potential Role of ALVR109 for the Treatment of COVID-19

Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.

Paulina J Haight, MD

Latest:

Dr Haight on Predictors of Treatment Toxicity in Gynecologic Malignancies

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Natalie I. U. Vokes, MD

Latest:

Dr Vokes on Targeting HER3 in NSCLC

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

Steven J. Chmura, MD, PhD

Latest:

Dr. Chmura on the Management of Oligometastatic Breast Cancer

Steven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.

Prithviraj Bose, MD, MD Anderson Cancer Center

Latest:

Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell Leukemia

The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.

Ken Culver, MD

Ken Culver, MD, is the director of Research and Clinical Affairs at ALK Positive Inc

Latest:

How a Career of Hearing and Amplifying Patient Voices Has Reached the Pinnacle of Patient Advocacy: With D. Ross Camidge, MD, PhD; and Ken Culver, MD

Drs Camidge and Culver discuss the highlights of Dr Culver's career, shaped by clinical practice, research, leadership, and patient advocacy.

Andrew John Armstrong, MD, MSc

Latest:

Biomarkers, Disease Tracking, and Tumor Evolution

A panel of experts discuss emerging data and future directions in AVPC/NEPC and mCRPC, including novel biomarkers for monitoring disease progression and treatment response (ctDNA, CTCs, CEA, LDH, chromogranin, imaging frequency) when PSA is unreliable, and promising therapeutic strategies such as MYC inhibitors, bispecific antibodies, antibody-drug conjugates, and radioligand therapies.

Ryan M. Khan, MD, MHS, FACOG

Ryan Matthew Kahn, M.D., MHS, FACOG, is a gynecologic oncologist at Baptist Health Miami Cancer Institute.

Latest:

Dr Kahn on Recognizing Surgical Limitations in Advanced Ovarian Cancer During Ovarian Cancer Awareness Month

Ryan Matthew Kahn, MD, MHS, FACOG, discusses the importance of recognizing surgical limitations in the treatment of patients with advanced ovarian cancer.

Amy Valley, PharmD

Latest:

Community-Based Oncology Practices Adapt to Uncertainty of Pandemic

The impact of COVID-19 has been felt deeply by community-based oncologists.

Tilak Sundaresan, MD

Latest:

Dr Sundaresan on Reasons Why Patients With Pancreatic Cancer May Decline Treatment

Tilak Sundaresan, MD, on results of a retrospective study of reasons why patients with pancreatic cancer decline treatment.

Christian S. Hinrichs, MD

Latest:

Dr. Hinrichs on Unmet Needs with Cellular Therapy in Metastatic Epithelial Cancer

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Marc R. Matrana, MD

Marc R. Matrana, MD, is a medical oncologist and director of Genitourinary Medical Oncology Research at Ochsner MD Anderson Cancer Center, as well as a professor of internal medicine at The University of Queensland Medical School – Ochsner Health.

Latest:

Dr Matrana on the Persisting Need For Validated Biomarkers to Guide Treatment Selection in RCC

Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.

Charles Schiffer, MD

Latest:

Dr. Schiffer on Factors to Consider for TKI Discontinuation in CML

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.